275 related articles for article (PubMed ID: 22513940)
1. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006282. PubMed ID: 22513940
[TBL] [Abstract][Full Text] [Related]
2. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006282. PubMed ID: 22161400
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment for spinal muscular atrophy types II and III.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment for spinal muscular atrophy types II and III.
Bosboom W; Vrancken AF; van den Berg LH; Wokke JH; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006282. PubMed ID: 19160275
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van der Pol WL; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2012 Apr; (4):CD006281. PubMed ID: 22513939
[TBL] [Abstract][Full Text] [Related]
6. Drug treatment for spinal muscular atrophy type I.
Wadman RI; Bosboom WM; van den Berg LH; Wokke JH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006281. PubMed ID: 22161399
[TBL] [Abstract][Full Text] [Related]
7. Drug treatment for spinal muscular atrophy type I.
Bosboom W; Vrancken AF; van den Berg LH; Wokke J; Iannaccone ST
Cochrane Database Syst Rev; 2009 Jan; (1):CD006281. PubMed ID: 19160274
[TBL] [Abstract][Full Text] [Related]
8. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
9. Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.
Diana A; Pillai R; Bongioanni P; O'Keeffe AG; Miller RG; Moore DH
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006049. PubMed ID: 28067943
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological treatment for pain in Guillain-Barré syndrome.
Liu J; Wang LN; McNicol ED
Cochrane Database Syst Rev; 2013 Oct; (10):CD009950. PubMed ID: 24142399
[TBL] [Abstract][Full Text] [Related]
11. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults.
Linde M; Mulleners WM; Chronicle EP; McCrory DC
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD010609. PubMed ID: 23797675
[TBL] [Abstract][Full Text] [Related]
12. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
[TBL] [Abstract][Full Text] [Related]
13. Creatine for treating muscle disorders.
Kley RA; Vorgerd M; Tarnopolsky MA
Cochrane Database Syst Rev; 2007 Jan; (1):CD004760. PubMed ID: 17253521
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
[TBL] [Abstract][Full Text] [Related]
15. Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease.
Radunovic A; Annane D; Rafiq MK; Mustfa N
Cochrane Database Syst Rev; 2013 Mar; (3):CD004427. PubMed ID: 23543531
[TBL] [Abstract][Full Text] [Related]
16. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
Vogel AP; Folker J; Poole ML
Cochrane Database Syst Rev; 2014 Oct; (10):CD008953. PubMed ID: 25348587
[TBL] [Abstract][Full Text] [Related]
17. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
18. A placebo-controlled trial of gabapentin in spinal muscular atrophy.
Miller RG; Moore DH; Dronsky V; Bradley W; Barohn R; Bryan W; Prior TW; Gelinas DF; Iannaccone S; Kissel J; Leshner R; Mendell J; Mendoza M; Russman B; Samaha F; Smith S;
J Neurol Sci; 2001 Oct; 191(1-2):127-31. PubMed ID: 11677003
[TBL] [Abstract][Full Text] [Related]
19. Physical therapy for Bell's palsy (idiopathic facial paralysis).
Teixeira LJ; Valbuza JS; Prado GF
Cochrane Database Syst Rev; 2011 Dec; (12):CD006283. PubMed ID: 22161401
[TBL] [Abstract][Full Text] [Related]
20. Creatine for treating muscle disorders.
Kley RA; Tarnopolsky MA; Vorgerd M
Cochrane Database Syst Rev; 2011 Feb; (2):CD004760. PubMed ID: 21328269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
